Phase 1/1B Open-Label, Dose-Escalation Study of APVO436 in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High-Grade Myelodysplastic Syndrome (MDS)
Phase of Trial: Phase I
Latest Information Update: 19 Jan 2019
At a glance
- Drugs APVO-436 (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- Sponsors Aptevo Therapeutics
- 13 Dec 2018 According to an Aptevo Therapeutics media release, top-line data are anticipated in late 2019.
- 13 Dec 2018 Status changed from not yet recruiting to recruiting, according to an Aptevo Therapeutics media release.
- 13 Dec 2018 According to an Aptevo Therapeutics media release, first patient has been dosed.